scorecardresearch

Pharma

The trial is being conducted by categorising children as per their age wherein 175 children of each age group have been included

Results of Covaxin trials on children expected by Sept: AIIMS chief

Jul 24, 2021

"The vaccines for children should come out now because trials in India are already there in the vaccines which are available in India, the Bharat Biotech trial is in the final phase by September we will have the data," Dr Guleria told ANI

Moderna's COVID-19 vaccine was granted emergency use authorisation by India's drug regulator last month

India may not get Moderna COVID-19 vaccine till 2022

Jul 24, 2021

The Centre is still holding discussions with the US-based pharma company regarding the production of its mRNA technology-based COVID-19 vaccine as part of the country's vaccination programme

Bharat Biotech has terminated a memorandum of understanding to sell its COVID-19 vaccine Covaxin to Brazil's Precisa Medicamentos (Source:Reuters)

Bharat Biotech terminates MoU to sell Covaxin to Brazil's Precisa Medicamentos

Jul 23, 2021

Bharat's statement said it will continue to work with Brazilian healthcare regulator Anvisa to obtain all required approvals for the use of Covaxin in the country

At full operational capacity, the annual COVID-19 vaccine production will target 100 million finished doses annually

Biovac-Pfizer collaboration a breakthrough for Covid in Africa: Cyril Ramaphosa

Jul 23, 2021

Biovac has been appointed to manufacture the Pfizer-BioNTech COVID-19 vaccine for distribution within Africa, making it the first company on the continent to produce an mRNA-based vaccine

Serum Institute of India writes to Health Minister

Serum writes to Health Minister to propose reforms in drug regulatory system

Jul 22, 2021

Prakash Kumar Singh, Director, Government and Regulatory Affairs at Pune-based SII, in a letter, referred to a gazette notification by the Union Health Ministry on May 18, 2020

The price of each dose of Covishield amounts to Rs 215.25 and Covaxin Rs 225.75, including taxes

Centre to procure 66 cr additional Covishield, Covaxin doses at revised prices

Jul 17, 2021

A total of 375 million of Covishield doses from the Serum Institute of India and 285 million Covaxin doses from Bharat Biotech will be procured by December

The Centre will procure 28.5 crore of Covaxin doses from Bharat Biotech and 37 crore of Covishield doses from SII by December

COVID-19 vaccine: Centre raises procurement price of Covaxin, Covishield

Jul 17, 2021

The price for a dose of Covishield has been increased to Rs 205 plus 5% GST, whereas the price for a dose of Covaxin has been hiked to Rs 215 plus 5% GST

Zydus Cadila had on July 1, applied for emergency use authorisation (EUA) of its ZyCoV-D three-dose Covid-19 vaccine - the world's first plasmid DNA vaccine

Zydus Cadila’s COVID-19 vaccine for 12-18 year olds to be available soon: Centre

Jul 16, 2021

Zydus Cadila TEMPhas completed its trial for children aged between 12 and 18 years and is subject to statutory approvals, teh government said in an affidavit submitted with teh Delhi High Court

Both Moderna and Pfizer have sought legal indemnity in case of any adverse effects of their vaccine

COVID-19 vaccine: Pfizer, Moderna have not submitted applications for EUA, says DCGI

Jul 15, 2021

This is the third time the Indian drug regulator has appealed Pfizer to file application papers to bring its vaccine to India

J&J said consumers should stop using the affected products and appropriately discard them

J&J recalls Aveeno, Neutrogena sunscreens after carcinogen detected in samples

Jul 15, 2021

After internal testing identified low levels of benzene in some samples, J&J said it has decided to recall these products from the market

 Sputnik V vaccine has been registered in 67 countries globally, covering a total population of over 3.5 billion people

Sputnik V may get WHO approval by October, says RDIF CEO

Jul 14, 2021

The first batch of Sputnik V is likely to be manufactured at Serum Institute's facilities in September said Kirill Dmitriev, CEO, Russian Direct Investment Fund (RDIF)